The Readout Loud 349: BIO's John Crowley on RFK Jr. and tariffs, plus calls for more federal biotech funding
19 snips
Apr 10, 2025 In this engaging conversation, John Crowley, CEO of the industry lobbying group BIO, discusses pressing issues in biotechnology. He sheds light on recent FDA layoffs and the implications for vaccine approval, particularly regarding Novavax's COVID-19 vaccine. Crowley addresses the critical need for a $15 billion federal investment to bolster U.S. biotech against competition from China. He also touches on the complexities surrounding public trust in science, the impact of tariffs on the industry, and how to navigate dialogues with controversial figures like RFK Jr.
AI Snips
Chapters
Transcript
Episode notes
Crowley's Personal Journey
- John Crowley's efforts to treat his children's Pompe disease led to founding Amicus Therapeutics.
- This journey was depicted in a book and a movie starring Brendan Fraser.
Biotech's Potential and Challenges
- Biotech has immense potential to alleviate human suffering, but man-made problems hinder progress.
- Crowley emphasizes the need to address these challenges through policy and collaboration.
Engaging with Appointees
- BIO engages constructively with presidential appointees, even those with differing views.
- Focus on finding common ground and voicing concerns when policies harm the industry.